Herceptin News and Research

RSS
TAU researcher develops new antibodies to target and destroy cancer cells

TAU researcher develops new antibodies to target and destroy cancer cells

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Panobinostat able to target and destroy triple negative breast cancer

Panobinostat able to target and destroy triple negative breast cancer

Researchers sequence genomes of 21 breast cancers

Researchers sequence genomes of 21 breast cancers

Halozyme first quarter net loss increases to $15.1 million

Halozyme first quarter net loss increases to $15.1 million

PDL first quarter total revenues decrease to $77.3 million

PDL first quarter total revenues decrease to $77.3 million

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma third quarter revenue increases to $19.1M

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Breast cancer treatment and classification revolutionized in landmark study

Breast cancer treatment and classification revolutionized in landmark study

Soon a vaccine that targets 90% of all cancers

Soon a vaccine that targets 90% of all cancers

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

TGen to present TNBC study at AACR 2012 annual meeting

TGen to present TNBC study at AACR 2012 annual meeting

Study identifies key mechanism behind breast cancer metastasis

Study identifies key mechanism behind breast cancer metastasis

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

Scientists study organ development in mice to unravel how breast cancers develop in people

Scientists study organ development in mice to unravel how breast cancers develop in people

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

FDA accepts Genentech's pertuzumab BLA and grants Priority Review